Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.
Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...
Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability ...
Innovent: Phase 2/3 Study Of Sintilimab Combination Meets Main Goal In Advanced Renal Cell Carcinoma
which evaluated sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China, has met its primary endpoint of ...
Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and ...
UW Health oncologist Dr. Nameer Mardini explains that this is a type of cancer that starts in the kidney when cells in the body grow out of control. As more cancer cells develop, they can form a tumor ...
Background: Thioredoxin reductase (Trx) has been implicated in activation of hypoxia-inducible factor-1α, which is overexpressed in > 85% of renal cell ... Those with tumor response or stable ...
Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory ...
EXEL discovers, develops, and commercializes new treatments to battle hard-to-treat cancers. Its product portfolio continues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback